| Cas No.: | 298197-04-3 |
| Chemical Name: | Fatostatin HBr |
| Synonyms: | Fatostatin A Hydrobromide;fatostatin;Fatostatin (hydrobromide);Fatostatin A;2-(2-propylpyridin-4-yl)-4-p-tolylthiazole hydrobromide;FATOSTATIN (2-(2-PROPYLPYRIDIN-4-YL)-4-(P-TOLYL)THIAZOLE);25B11 hydrobromide;4-[4-(4-methylphenyl)-2-thiazolyl]-2-propylpyridine hydrobromide;Fatostatin HBr;Fatostatin A HBr;Fatostatin Hydrobromide;2-(2-Propylpyridin-4-yl)-4-(p-tolyl)thiazole hydrobromide;SMR000221636;2-Propyl-4-(4-p-tolyl-thiazol-2-yl)-pyridine;MLS000332366;C18H19BrN2S;MLS003593148;BCP20908;s8284;Fatostatin A Hydrobromide;Fatostatin A;AX8289397;4-[4-(4-Methylphenyl)-2-thiazolyl]-2-propylpyr |
| SMILES: | Br[H].S1C([H])=C(C2C([H])=C([H])C(C([H])([H])[H])=C([H])C=2[H])N=C1C1C([H])=C([H])N=C(C=1[H])C([H])([H])C([H])([H])C([H])([H])[H] |
| Formula: | C18H19BrN2S |
| M.Wt: | 375.328 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice[1][2]. |
| In Vivo: | Fatostatin hydrobromide (125B11 hydrobromide) (30 mg/kg; 150 mL; i.p.; daily for 28 days) reduces adiposity, ameliorates fatty liver by reducing triglyceride (TG) storage, and lowers hyperglycemia in ob/ob mice[2]. Animal Model: Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)[2] Dosage: 30 mg/kg; 150 mL Administration: i.p. injection; daily for 28 days Result: Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake. |
| In Vitro: | Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin hydrobromide inhibits insulin-induced adipogenesis of 3T3-L1 cells[1]. Cell Proliferation Assay[1] Cell Line: DU-145 cells Concentration: 0.1, 1 μM Incubation Time: 3 days Result: Impaired the IGF1-induced growth at an IC50 of 0.1 μM. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
